|Targets||CDK | CK1|
|Description||The hydrochloride salt form of (R)-DRF053, which is a cdk/CK1 inhibitor and could be used in studies in the cancer treatment with combinations of CDK kinase and ERK inhibitors.|
|Purity||≥98% by HPLC|
Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Selicicl...
Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-depen...
Ryuvidine, a cell-permeable dioxobenzothiazole compound, is an inhibitor of SETD8 (IC50 = 0.5 µM) that suppresses monomethylation of H4K20 in vitro.1 It less po...
3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a ribonucleotide reductase inhibitor and iron chelator with anti-tumor activity.
Alvocidib is a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by p...
AT7519 is an ATP competitive CDK inhibitor with a Ki value of 38 nM for CDK1. AT7519 is inactive against all non-CDK kinases with the exception of GSK3β (IC50 =...
AZD5438 is a potent inhibitor of cyclin-dependent kinase (cdk) 1, 2, and 9 (IC(50), 16, 6, and 20 nmol/L, respectively). Broad cdk inhibition may provide an eff...
SR-3029, a small molecule inhibitor that targets specificly CK1δ/CK1ε, was effective at reducing the growth of breast cancer in multiple mouse models without an...
IC261, also known as SU5607, is a potent and selective CK1 inhibitor. IC261 triggers the mitotic checkpoint and induces p53-dependent postmitotic effects.
CYC065 is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases with potential antineoplastic and chemoprotective activities.
THZ2, an analog of THZ1, with the potential to treat Triple-negative breast cancer (TNBC), it is a potent and selective CDK7 inhibitor which overcomes the insta...
PF 5006739 is a potent inhibitor of casein kinases 1 delta (CK1δ) and 1 epsilon (CK1ε) (IC50 values are 3.9 and 17 nM, respectively). It mediates circadian rhyt...
PF 4800567 hydrochloride
PF 4800567 is a casein kinase 1e (CK1e) selective inhibitor that is 22 fold selective for the CK1e isoform over CK1d (IC50= 32 and 711 nM for CK1ε and CK1δ resp...
LH846 is a selective inhibitor of CK1δ, which displays no inhibitory activity at CK2. It inhibits CK1δ-dependent phosphorylation and degradation of PER1 protei...
LDC4297 is a potent and selective cyclin-dependent protein kinase 7 (CDK7) inhibitor with an IC50 of 0.13 nM.
BAY 1143572 is a highly selective, potent and orally available inhibitor ofPTEFb/CDK9 and shows convincing anti-tumor activity in multiple xenograft models by t...
SNS-032, also known as BMS-387032, is a 2-aminothiazole-derived, small-molecule cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. ...
PF-670462 is a potent and selective inhibitor of CK1ε in isolated enzyme preparations. It inhibits PER protein nuclear translocation causing phase shifts in cir...
The hydrochloride salt form of (R)-DRF053, which is a cdk/CK1 inhibitor and could be used in studies in the cancer treatment with combinations of CDK kinase and...
Riviciclib, also known as P276-00, is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. P276-00 selectively binds to and ...